{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:02:37Z","timestamp":1761901357695,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Medical Faculty of Charles University","award":["Q40"],"award-info":[{"award-number":["Q40"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.msard.2017.08.020","type":"journal-article","created":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T17:39:56Z","timestamp":1504719596000},"page":"29-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Lymphocytes in the treatment with interferon beta-1 b"],"prefix":"10.1016","volume":"18","author":[{"given":"Zby\u0161ek","family":"Pavelek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Old\u0159ich","family":"Vy\u0161ata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanka","family":"Kl\u00edmov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ctirad","family":"Andr\u00fds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Vokurkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Vali\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2017.08.020_bib1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/WCO.0b013e3282febf58","article-title":"Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system","volume":"21","author":"Anderton","year":"2008","journal-title":"Curr. Opin. Neurol."},{"issue":"29","key":"10.1016\/j.msard.2017.08.020_bib2","doi-asserted-by":"crossref","first-page":"22328","DOI":"10.1074\/jbc.M110.123299","article-title":"CD69 suppresses sphingosine 1-phosophate receptor-1 (S1P1) function through interaction with membrane helix 4","volume":"285","author":"Bankovich","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.msard.2017.08.020_bib3","doi-asserted-by":"crossref","first-page":"e39576","DOI":"10.1371\/journal.pone.0039576","article-title":"Activated human CD4+CD45RO+ memory T-cells indirectly inhibit NLRP3 inflammasome activation through downregulation of P2X7R signalling","volume":"7","author":"Beynon","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.msard.2017.08.020_bib4","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1172\/JCI119571","article-title":"Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b","volume":"100","author":"Chabot","year":"1997","journal-title":"J. Clin. Investig."},{"issue":"9","key":"10.1016\/j.msard.2017.08.020_bib5","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1002\/eji.200838879","article-title":"Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS","volume":"39","author":"Chen","year":"2009","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2017.08.020_bib6","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/eji.200738104","article-title":"Human regulatory T cells and autoimmunity","volume":"38","author":"Costantino","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"10","key":"10.1016\/j.msard.2017.08.020_bib7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.molmed.2013.07.006","article-title":"Is CD69 an effective brake to control inflammatory diseases?","volume":"19","author":"Gonz\u00e1lez-Amaro","year":"2013","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.msard.2017.08.020_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1352458514561911","article-title":"The Charcot Lecture | beating MS: a story of B cells, with twists and turns","volume":"21","author":"Hauser","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2017.08.020_bib9","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.0b013e3181c97c8f","article-title":"Multiple sclerosis immunology: the healthy immune system vs. the MS immune system","volume":"74","author":"Kasper","year":"2010","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2017.08.020_bib10","first-page":"236","article-title":"Imunopatogeneze roztrou\u0161en\u00e9 skler\u00f3zy. [Immunopathogenesis of multiple sclerosis.]","volume":"3","author":"Krejsek","year":"2002","journal-title":"Neurol. Pro Praxi"},{"issue":"10","key":"10.1016\/j.msard.2017.08.020_bib11","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1074\/jbc.M008573200","article-title":"Crystal structure of the C-type lectin-like domain from the human hematopoietic cell receptor CD69","volume":"276","author":"Llera","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.msard.2017.08.020_bib12","first-page":"1015","article-title":"Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer","volume":"79","author":"Lou","year":"1999","journal-title":"Lab. Investig."},{"issue":"2","key":"10.1016\/j.msard.2017.08.020_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/intimm\/dxq463","article-title":"Impaired IFN-\u03b3 production and proliferation of NK cells in multiple sclerosis","volume":"23","author":"L\u00fcnemann","year":"2011","journal-title":"Int. Immunol."},{"issue":"24 Suppl 4","key":"10.1016\/j.msard.2017.08.020_bib14","first-page":"S8","article-title":"Interferon-beta: mechanism of action and dosing issues","volume":"68","author":"Markowitz","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2017.08.020_bib15","first-page":"13478","article-title":"VCAM1 acts in parallel with CD69 and is required for the initiation of oligodendrocyte myelination. Nature","volume":"7","author":"Miyamoto","year":"2016","journal-title":"Communications"},{"issue":"1\u20132","key":"10.1016\/j.msard.2017.08.020_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jns.2005.02.013","article-title":"The activation of memory CD4(+) T cells and CD8(+) T cells in patients with multiple sclerosis","volume":"235","author":"Okuda","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2017.08.020_bib17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2017.08.020_bib18","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2017.08.020_bib19","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/icb.2016.55","article-title":"Interferon-\u03b2 therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis","volume":"94","author":"Rizzo","year":"2016","journal-title":"Immunol. Cell Biol."},{"issue":"3","key":"10.1016\/j.msard.2017.08.020_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10072-007-0803-3","article-title":"Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta","volume":"28","author":"Saraste","year":"2007","journal-title":"Neurol. Sci."},{"issue":"7083","key":"10.1016\/j.msard.2017.08.020_bib21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nature04606","article-title":"CD69 acts downstream of interferon-alpha\/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs","volume":"440","author":"Shiow","year":"2006","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.msard.2017.08.020_bib22","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/ni0901-762","article-title":"Multiple sclerosis: a two-stage disease","volume":"2","author":"Steinman","year":"2001","journal-title":"Nat. Immunol."},{"issue":"6013","key":"10.1016\/j.msard.2017.08.020_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.msard.2017.08.020_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2567.2006.02518.x","article-title":"Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis","volume":"121","author":"Zafranskaya","year":"2007","journal-title":"Immunology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034817302031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034817302031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:41:33Z","timestamp":1761900093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034817302031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":24,"alternative-id":["S2211034817302031"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2017.08.020","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphocytes in the treatment with interferon beta-1 b","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2017.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}